General Information of Drug (ID: DMVTLF9)

Drug Name
(10r)-10-Formyl-5,8,10-Trideazafolic Acid Drug Info
Synonyms
(10R)-10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID; NHR; 2-{4-[2-(2-AMINO-4-HYDROXY-QUINAZOLIN-6-YL)-1-CARBOXY-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; 1c3e; AC1L9GSR; DB04264; 8937-EP2308866A1; 8937-EP2308846A2; 8937-EP2305697A2; 8937-EP2298780A1; 8937-EP2277872A1; 8937-EP2316829A1; 8937-EP2308872A1; 8937-EP2308845A2; 8937-EP2305698A2; 8937-EP2305695A2; 8937-EP2301932A1; 8937-EP2287167A1; 8937-EP2283898A1; 8937-EP2281563A1; 8937-EP2316459A1; 8937-EP2308844A2; 8937-EP2277869A1; 8937-EP2270018A1; 8937-EP2308812A2; 8937-EP2305696A2
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
135460968
TTD Drug ID
DMVTLF9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PELITREXOL DMR6USG Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
LY309887 DMJPCHK Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
10-Formyl-5,8,10-Trideazafolic Acid DMEBHML Discovery agent N.A. Investigative [1]
Glycinamide Ribonucleotide DMW180Y Discovery agent N.A. Investigative [1]
10-trifluoroacetyl-DDACTHF DMEAGI6 Discovery agent N.A. Investigative [4]
Dideazaacyclotetrahydrofolic acid DM9WU3R Discovery agent N.A. Investigative [5]
10-CF3C(OH)2-DDACTHF DMQOUJ7 Discovery agent N.A. Investigative [1]
Dideazafolate DMAIOC9 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycinamide ribonucleotide formyltransferase (GART) TTEXB9Z PUR2_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075.
3 New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 Suppl 3:1-7.
4 Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase. J Med Chem. 2006 May 18;49(10):2998-3002.
5 Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 2008 Sep 11;51(17):5441-8.
6 N10-substituted 5,8-dideazafolate inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 1987 Jul;30(7):1254-6.